USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

Pfizer updates on Phase 3 study of investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy

The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment

Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment

Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners

Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine

Honeywell introduces batch historian to digitalize manufacturing operations

New software solution helps manufacturers digitalize and gain insights from data to increase efficiency

Abbott wins CE mark for dual-chamber leadless pacemaker

Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers

Fischer Medical Venture and BluSim Tech partner to redefine elderly care

his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio

Neuland unveils refreshed brand identity

The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress

Ecolab and Repligen launch DurA Cycle affinity resin for biologic manufacturing

DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,

Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis

New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH